The portfolio-level pattern first: in mRNA therapeutics, delivery is where the patents cluster. Across the lipid-nanoparticle and mRNA-delivery record, the heaviest assignees include Moderna, Alnylam Pharmaceuticals, the University of Massachusetts, MIT, the University of Pennsylvania, and Translate Bio. The instructive part is what they are claiming: not the therapeutic mRNA sequence, but the formulation — the ionizable lipids, the particle composition, and the process for loading mRNA into the particle.
Translate Bio's holdings show the manufacturing-process layer clearly. US12053551B2, "Process of preparing mRNA-loaded lipid nanoparticles" (issued August 6, 2024; CPC A61K 9/5192), claims a method of making the loaded particle. Process claims are strategically distinct from composition claims: even a developer who designs around a composition can be blocked by a process claim if the practical manufacturing route falls within it. The presence of process claims alongside composition claims is what makes the LNP estate hard to navigate.
Composition-level claims define the other half. US12011507B2, "mRNA delivery composition" (NanoVation Therapeutics, issued June 18, 2024; CPC A61K 9/5123), and US12576030B2, "Compositions for delivery of codon-optimized mRNA" (Translate Bio, issued March 17, 2026; CPC A61K 9/1272), claim the delivered article itself. The codon-optimization framing in the latter is notable — it couples a payload-engineering feature to the delivery composition, narrowing the claim but tying two innovations together.
The white space sits between the heavily-claimed ionizable-lipid chemistries and the specific particle ratios. Because the foundational ionizable-lipid and particle-composition space is densely held, new entrants tend to file around it — novel lipid structures, alternative particle architectures, or process improvements. The fact that an academic-heavy assignee list (Penn, MIT, UMass) sits beside the companies means much of the foundational chemistry is licensable rather than exclusively corporate, which shapes how a new mRNA developer should plan its freedom-to-operate.
Filing velocity in the LNP/mRNA-delivery record rose sharply through the early 2020s, consistent with a platform that went from niche to central. The strategic read of that velocity: the field is past the point where a single broad delivery claim could dominate, and into the phase where overlapping composition and process claims from multiple holders create a dense, license-or-design-around landscape.
The conclusion for a strategist: when you map an mRNA program's IP risk, weight the delivery estate over the payload. The composition claims (what the particle is) and the process claims (how it is made) together form the gating layer, held by a company-plus-academic mix. The mRNA sequence may be yours; whether you can deliver it is decided in the lipid-nanoparticle patents.